BBI News and Press, Brickell Biotech Inc. From 03/15/22

Brickell Biotech, Inc. (BBI) Q4 2021 Earnings Conference Call March 15, 2022 08:30 AM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Andrew Sklawer - Co-Founder & Chief Operating Officer Albert Marchio II - Chief Financial Officer Monic...

The following slide deck was published by Brickell Biotech, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Brickell Biotech, Inc. 2021 Q4 - Results - Earnings Call Presentation

Brickell Biotech press release (NASDAQ:BBI): Q4 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.1M (+233.3% Y/Y) misses by $0.05M. The company reported cash and cash equivalents of $26.9M and expects it to support operations beyond the receipt of Phase 1 SAD and MAD topline results for ...

Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On track to initiate P...

Brickell Biotech (NASDAQ:BBI) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is -$0.09 (+40.0% Y/Y) and the consensus Revenue Estimate is $0.15M (-44.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward rev...

ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutic...

BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutic...

Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell’s pipeline in immunology and inflammation and leverages its drug development ca...

3 High Volume Penny Stocks For Your January Watchlist While trading penny stocks and blue chips has gotten off to a rough start this week, many investors are optimistic about the future. With the Dow Jones Industrial Average down by more than 500 points and the S&P 500 down by aroun...